Key facts
- This page summarizes Daniel Gruskin's Form 3 filing for LogicBio Therapeutics, Inc..
- 0 reported transactions and 3 derivative rows are listed below.
- Accepted by SEC: 20 May 2021, 20:33.
Daniel Gruskin - 19 May 2021 Form 3 Insider Report for LogicBio Therapeutics, Inc.
- Reporting relationship
- Chief Medical Officer
- Issuer ticker
- N/A
- Reported as of
- 19 May 2021
- Net transaction value
- $0
- SEC form
- 3
- Accepted by SEC
- 20 May 2021, 20:33:26 UTC
- Next SEC filing
- 10 Aug 2021
- Source filing
- View source filing
- Reporting owner signature
- /s/ Jonathan Quick, as Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Filing notes and source
Key filing fact
Daniel Gruskin filed Form 3 for LogicBio Therapeutics, Inc. on 20 May 2021.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Official SEC source
View source filing
Ownership activity is grounded in SEC Form 3 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
LOGC
holding
Derivative
Employee Stock Option (Right to buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 19 May 2021
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 85,000
- Exercise price
- $7.92
- Footnotes
- F1
LOGC
holding
Derivative
Employee Stock Option (Right to buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 19 May 2021
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 155,701
- Exercise price
- $7.76
- Footnotes
- F2
LOGC
holding
Derivative
Restricted Stock Units
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 19 May 2021
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 4,798
- Exercise price
- $0.000000
- Footnotes
- F3, F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 4 footnotes
Footnote F1
The options were granted by the Issuer pursuant to its 2018 Equity Incentive Plan. The options will vest over four years: 25% of the options will vest on the August 6, 2021 with the remaining 75% vesting in equal monthly installments thereafter, subject to the reporting person's continued service with the Issuer on each vesting date.
Footnote F2
The options were granted by the Issuer pursuant to its 2018 Equity Incentive Plan. The options will vest over four years: 25% of the options will vest on January 1, 2022 with the remaining 75% vesting in equal monthly installments thereafter, subject to the reporting person's continued service with the Issuer on each vesting date.
Footnote F3
Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.
Footnote F4
The RSUs will fully vest on August 6, 2021, subject to the terms and conditions of the award and the Issuer's 2018 Equity Incentive Plan; provided, that if the reporting person's employment is terminated by the Issuer without "cause" or by the reporting person for "good reason" (as defined in the reporting person's employment agreement) prior to August 6, 2021, all such RSUs will vest on the date of termination.